Switch to:
More From Other Websites
VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 29 2015
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile... Jan 29 2015
VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile... Jan 29 2015
7:00 am Vivus announces that the European Commissionhas adopted the commission implementing decision... Jan 29 2015
VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 27 2015
VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 26 2015
Coverage initiated on Vivus by RBC Capital Mkts Jan 23 2015
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 15 2015
VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2015
VIVUS to Present at Upcoming Investor Conference Jan 09 2015
VIVUS to Present at Upcoming Investor Conference Jan 09 2015
FDA clears Novo Nordisk's weight loss drug Saxenda Dec 23 2014
FDA clears Novo Nordisk's weight loss drug Saxenda Dec 23 2014
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Dec 19 2014
Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators Dec 19 2014
Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
VIVUS Announces Favorable Formulary Positioning for Qsymia Dec 15 2014
VIVUS Announces Favorable Formulary Positioning for Qsymia Dec 15 2014
Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Dec 12 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK